Promoter holding
64.27%
CE
Cytozyme Eastern India Pvt Ltd - Due diligence report
A 360° intelligence report on Cytozyme Eastern India Pvt Ltd: trust score, financial health, credit view, compliance, directors, growth and …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Cytozyme Eastern India Pvt Ltd — 360° Intelligence Report
Generated from MCA filings & public records81/100
Trust Score
Low Risk
Cytozyme Eastern India Pvt Ltd is assessed as Low Risk with a Trust Score of 81/100. Cytozyme Eastern India Pvt Ltd is an active private limited indian non-government company incorporated in 1980, operating in the Financial Services sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.
Report generated on 08 Aug 2026 from the latest processed filings. Cytozyme Eastern India Pvt Ltd snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
81/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
86/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
60/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
55/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 55/100 Moderate
- Liabilities ≈ 38% EBITDA - stretched.
- No open charges - unencumbered balance sheet.
- Moderate gearing (D/E 1.42).
Charges position: 0 open (-) · 0 satisfied (-).
Compliance Score: 86/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 2 court forum(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| SHEO SHANKAR PANDEY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAVI SHANKAR PANDEY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 2 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
06
Ownership & Group Intelligence
As per FY 2019 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 0 transfer(s)
Promoters hold the largest single block of equity - exact percentages are part of the full report.
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 55 · Distress 80
Growth signals & trust indicators
Latest year revenue grew 2.1x.
Asset base grew 24% - capacity expansion.
Operating for 46+ years.
Distress signals & risk flags
Outside liabilities up 0.86 in a year.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence83/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment64/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance record supports lending.
Investor view63/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 12 events30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
30 Sep 2014
Director ceased
SHEO SHANKAR PANDEY
03 Dec 2013
Director appointed
SHEO SHANKAR PANDEY (Director)
Director ceased
SANJAY KUMAR PANDIT
05 Jun 2012
Securities allotted
1485000 Equity Shares Without Differential Rights - 7.43 cr raised
01 Jun 2012
Director ceased
ASIS KUMAR BHATTACHARHEE
28 Sep 2011
Securities allotted
1251000 Equity Shares Without Differential Rights - 6.26 cr raised
01 Mar 2011
Director ceased
RABIN KUMAR BOSE
15 Dec 2010
Director appointed
RAVI SHANKAR PANDEY (Director)
15 Jun 2009
Director ceased
VITHAL DAS MALL
08 Jul 1980
Incorporated
Registered with Roc Kolkata I
10
Key Observations
Auto-generated from the data aboveRevenue declined 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
Promoters hold the largest single block of equity as per the FY 2019 annual return.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Erode M D Chit Funds Private Limited | U65992TZ2015PTC021376 | Erode, Tamil Nadu, India |
| Pkb Kuries (Vatanappilly) Private Limited | U65992KL2014PTC037016 | Thrissur, Kerala, India |
| Maruthi Mithra Chit Funds Private Limited | U65992AP1991PTC012549 | Vijayawada, Andhra Pradesh, India |
| Andheri Forex Private Limited | U67100MH2017PTC298571 | Mumbai, Maharashtra, India |
| Mantu Housing Projects Ltd | U45202WB1994PLC061583 | Kolkata, West Bengal, India |
| Hisar Farms And Investments Pvt Ltd | U01122HR1985PTC020729 | Haryana, Haryana, India |
| Nikhi Securities Private Limited | U67120TG1994PTC018463 | Premnagar Hyderbad.-500004., Telangana, India |
| Chadha Travels Pvt Ltd | U63040MP1972PTC001112 | Jabalpur, Madhya Pradesh, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Cytozyme Eastern India Pvt Ltd before audits and certifications: compliance score 86/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Cytozyme Eastern India Pvt Ltd: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 55/100, margin trends, ownership structure and peer set for Cytozyme Eastern India Pvt Ltd - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 81/100, distress signals and MSME payment-delay disclosures - know whether Cytozyme Eastern India Pvt Ltd pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Cytozyme Eastern India Pvt Ltd - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Cytozyme Eastern India Pvt Ltd an active company?
Cytozyme Eastern India Pvt Ltd has MCA status “Active” with a compliance score of 86/100 (Low Risk).
Is Cytozyme Eastern India Pvt Ltd financially healthy?
Cytozyme Eastern India Pvt Ltd has a Financial Health Score of 60/100 (Moderate) based on its filed financial statements.
Should I do business with Cytozyme Eastern India Pvt Ltd?
Its overall Trust Score is 81/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Cytozyme Eastern India Pvt Ltd?
Promoters hold the largest single block of equity - exact percentages are in the full report. 2 active director(s) are on record.
Does Cytozyme Eastern India Pvt Ltd have loans or charges against its assets?
No charges are registered against this company - an unencumbered balance sheet.
Is Cytozyme Eastern India Pvt Ltd up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 86/100 (Low Risk).
Is it risky to lend to Cytozyme Eastern India Pvt Ltd?
Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
